| Literature DB >> 34268254 |
Maha Mohamed Farid Aql1, Seham Abd-El Ghafour Bahget1, Naglaa Kholoussi2, Ghada Mohamed El Hossiny Abdel-Salam3, Haiam Abdel Raouf2, Maha Mohamed Eid4, Rania El-Bialy Esmail2.
Abstract
Telomeres are nucleoprotein complexes present at the ends of chromosome to maintain its integrity. Telomere length is maintained by an enzyme called "telomerase". Thus, telomerase activity and telomere length are crucial for the initiation of cancer and tumors survival. Also, oxidative stress will cause DNA, protein, and/or lipid damage, which end with changes in chromosome instability, genetic mutation, and may affect cell growth and lead to cancer. Some genetic diseases such as chromosomal instability syndrome, overgrowth syndrome, and neurofibromatosis make the patients at higher risk for developing different types of cancers. Therefore, we aimed to estimate telomerase activity and oxidative stress in these patients. Blood samples were collected from 31 patients (10 with neurofibromatosis, 11 with chromosomal breakage, and 10 with overgrowth syndrome) and 12 healthy subjects. Blood hTERT mRNA was detected by real time quantitative reverse-transcription PCR (RT-qPCR). All patients were subjected to chromosomal examination and chromosome breakage study using diepoxybutane method. Moreover, serum glutathione (GSH), glutathione-s-transferase (GST) activity and nitric oxide (NO) levels were measured among the control and patients groups. Receiver operating characteristic (ROC) curve was drawn to evaluate the efficiency of telomerase activity as a biomarker for the prediction of cancer occurrence. The relative telomerase activity in neurofibromatosis patients was significantly higher than controls (P = 0.014), while it was non-significantly higher in chromosomal breakage and overgrowth patients (P = 0.424 and 0.129, respectively). NO levels in neurofibromatosis, chromosomal breakage and overgrowth patients significantly increased with respect to control (P = 0.021, 0.002, 0.050, respectively). GSH levels were non-significantly lower in neurofibromatosis and chromosomal breakage patients in comparison with the control group, while it remained unchanged in overgrowth patients. The GST activity was significantly upregulated in neurofibromatosis, chromosomal breakage and overgrowth groups in comparison with the control group (P = 0.001, 0.009, and 0.025, respectively). Chromosomal examination revealed normal karyotype in all four chromosomal breakage patients with positive diepoxybutane test. The results of the present study revealed altered telomerase activity and oxidative stress in the studied genetic disorders. More research studies with a larger number of patients are required to confirm whether this alteration is related to cancer occurrence risk or not.Entities:
Keywords: Telomerase; chromosomal breakage; genetic disorder; neurofibromatosis; overgrowth; oxidative stress
Year: 2021 PMID: 34268254 PMCID: PMC8256828 DOI: 10.22088/IJMCM.BUMS.10.1.56
Source DB: PubMed Journal: Int J Mol Cell Med ISSN: 2251-9637
Fig. 1Percent of GSH results in all patients compared with control
Fig. 2Percent of TLC results in all patients compared with control
Fig. 3.Percent of Nitric Oxide results in all patients in relation to control
Fig. 4Percent of GST results in all patients in relation to control
Fig. 5Comparison of telomerase activity in different groups with the control group. *: Significance at P< 0.05 compared with control using Mann-Whitney Test
Correlations of studied parameters in neurofibromatosis patients (n=10).
|
|
|
|
|
|
|
|
|
| |
|---|---|---|---|---|---|---|---|---|---|
|
| -0.553 | 0.235 | 0.403 | -0.134 | 0.084 | 0.743 | 0.982** | 0.826* | |
|
| NS | -0.377 | -0.146 | -0.219 | -0.030 | -0.773* | -0.721 | -0.773* | |
|
| NS | NS | 0.433 | -0.350 | -0.500 | 0.577 | 0.214 | 0.468 | |
|
| NS | NS | NS | -0.467 | -0.188 | -0.072 | 0.036 | -0.180 | |
|
| NS | NS | NS | NS | 0.442 | -0.126 | 0.143 | 0.198 | |
|
| NS | NS | NS | NS | NS | -0.306 | -0.107 | -0.090 | |
|
| NS | P=0.042 | NS | NS | NS | NS | 0.775* | 0.918** | |
|
| P=0.000 | NS | NS | NS | NS | NS | P=0.041 | 0.883** | |
|
| P=0.022 | P=0.042 | NS | NS | NS | NS | P=0.004 | P=0.008 |
P value was calculated using Spearman correlation analysis: **: significant correlation at 0.01 level; *: significant correlation at 0.05 level; NS: non significance; OFC:
occipitofrontal circumference
Correlations of studied parameters in chromosomal breakage patients (n=11).
|
|
|
|
|
|
|
|
|
| |
|---|---|---|---|---|---|---|---|---|---|
|
| -0.171 | -0.073 | 0.171 | 0.098 | 0.195 | 0.439 | 0.439 | 0.160 | |
|
| NS | 0.164 | -0.327 | -0.164 | 0.555 | 0.055 | 0.064 | 0.404 | |
|
| NS | NS | -0.336 | -0.218 | -0.136 | -0.327 | -0.173 | 0.220 | |
|
| NS | NS | NS | -0.100 | -0.282 | -0.045 | 0.109 | -0.505 | |
|
| NS | NS | NS | NS | 0.218 | -0.118 | -0.173 | 0.257 | |
|
| NS | NS | NS | NS | NS | 0.073 | 0.064 | 0.486 | |
|
| NS | NS | NS | NS | NS | NS | 0.918** | 0.514 | |
|
| NS | NS | NS | NS | NS | NS | P=0.000 | 0.514 | |
|
| NS | NS | NS | NS | NS | NS | NS | NS |
P value was calculated using Spearman correlation analysis: **: significant correlation at 0.01 level; NS: non significance; OFC:
occipitofrontal circumference
Correlations of studied parameters in overgrowth patients (n=10)
|
|
|
|
|
|
|
|
|
| |
|---|---|---|---|---|---|---|---|---|---|
|
| -0.257 | 0.241 | -0.456 | -0.218 | 0.034 | 0.952** | 0.988** | 0.855** | |
|
| NS | -0.160 | 0.346 | -0.098 | -0.268 | -0.345 | -0.370 | -0.588 | |
|
| NS | NS | 0.033 | 0.050 | 0.017 | 0.017 | 0.100 | -0.183 | |
|
| NS | NS | NS | -0.444 | 0.450 | -0.477 | -0.636 | -0.452 | |
|
| NS | NS | NS | NS | -0.721* | 0.133 | 0.133 | 0.100 | |
|
| NS | NS | NS | NS | P=0.019 | -0.167 | -0.200 | -0.033 | |
|
| P=0.000 | NS | NS | NS | NS | NS | 0.950** | 0.917** | |
|
| P=0.000 | NS | NS | NS | NS | NS | P=0.000 | 0.867** | |
|
| P=0.007 | NS | NS | NS | NS | NS | P=0.001 | P=0.002 |
P value was calculated using Spearman correlation analysis: **: significant correlation at 0.01 level; *: significant correlation at 0.05 level; NS: non significance;
OFC: occipitofrontal circumference
Fig. 6.ROC Curve of Telomerase Result in Neurofibromatosis, Overgrowth, and Chromosomal Breakage Patients
Prediction results for studied parameters in all patients groups
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|
| Overgrowth | 0.783 | 172.938 | 80.0 % | 75.0 % | 12.000 | 72.70% | 81.80% | |
|
| Neurofibromatosis | 0.692 | 8.200 | 80.0 % | 58.3 % | 5.600 | 61.50% | 77.80% |
| Chromosomal breakage | 0.769 | 10.400 | 36.4 % | 91.7 % | 6.286 | 80.00% | 61.10% | |
| Overgrowth | 0.800 | 10.250 | 40.0 % | 91.7 % | 7.333 | 80.00% | 64.70% | |
|
| Neurofibromatosis | 0.725 | 0.278 | 88.9 % | 75.0 % | 24.000 | 72.70% | 90.00% |
| Chromosomal breakage | 0.904 | 0.862 | 45.5 % | 83.3 % | 4.167 | 71.40% | 62.50% | |
| Overgrowth | 0.602 | 0.028 | 100.0 % | 33.3 % | --- | 52.90% | 100.00% | |
|
| Neurofibromatosis | 0.598 | 10.170 | 70.0 % | 100.0 % | 5.000 | 100.00% | 80.00% |
| Chromosomal breakage | 0.864 | 9.746 | 72.7 % | 100.0 % | 5.000 | 100.00% | 80.00% | |
| Overgrowth | 0.606 | 9.746 | 60.0 % | 100.0 % | 4.000 | 100.00% | 75.00% | |
|
| Neurofibromatosis | 0.818 | 1.478 | 90.0 % | 58.3 % | 12.600 | 64.30% | 87.50% |
| Chromosomal breakage | 0.558 | 1.331 | 72.7 % | 66.7 % | 5.333 | 66.70% | 72.70% | |
| Overgrowth | 0.657 | 1.860 | 50.0 % | 75.0 % | 3.000 | 62.50% | 64.30% | |
|
| Neurofibromatosis | 0.742 | 501.945 | 80.0 % | 91.7 % | 44.000 | 88.90% | 84.60% |
| Chromosomal breakage | 0.529 | 150.443 | 81.8 % | 75.0 % | 13.500 | 75.00% | 81.80% |
OR: odd ratio; PPV: positive predictive value; NPV: negative predictive value